X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (100) 100
humans (99) 99
oncology (85) 85
cancer (54) 54
chemotherapy (54) 54
female (48) 48
male (46) 46
middle aged (43) 43
aged (37) 37
adult (35) 35
treatment outcome (28) 28
aged, 80 and over (24) 24
survival (24) 24
antineoplastic agents - therapeutic use (23) 23
tumors (22) 22
care and treatment (21) 21
prognosis (21) 21
metastasis (20) 20
mutation (20) 20
open-label (20) 20
patients (18) 18
therapy (18) 18
antineoplastic combined chemotherapy protocols - therapeutic use (17) 17
colorectal cancer (17) 17
lung cancer (17) 17
analysis (16) 16
clinical trials (16) 16
disease-free survival (16) 16
lung neoplasms - drug therapy (15) 15
colorectal neoplasms - pathology (14) 14
research (14) 14
retrospective studies (14) 14
adenocarcinoma (13) 13
metastases (13) 13
multidisciplinary sciences (13) 13
quality of life (13) 13
respiratory system (13) 13
bevacizumab (12) 12
cancer therapies (12) 12
colorectal neoplasms - drug therapy (12) 12
expression (12) 12
immunohistochemistry (12) 12
neoplasms (12) 12
1st-line treatment (11) 11
australia (11) 11
cisplatin (11) 11
diagnosis (11) 11
hematology, oncology and palliative medicine (11) 11
immunotherapy (11) 11
medicine (11) 11
randomized controlled trials as topic (11) 11
trial (11) 11
cell lung-cancer (10) 10
double-blind (10) 10
lung cancer, non-small cell (10) 10
lung neoplasms - pathology (10) 10
studies (10) 10
toxicity (10) 10
animals (9) 9
cell line, tumor (9) 9
cetuximab (9) 9
combination chemotherapy (9) 9
fluorouracil (9) 9
liver metastases (9) 9
medical prognosis (9) 9
mesothelioma (9) 9
mesothelioma - drug therapy (9) 9
neoplasm staging (9) 9
phase-iii trial (9) 9
randomized controlled-trial (9) 9
surgery (9) 9
survival analysis (9) 9
survival rate (9) 9
antineoplastic agents - pharmacology (8) 8
article (8) 8
cell biology (8) 8
health aspects (8) 8
leucovorin (8) 8
liver neoplasms - secondary (8) 8
lung neoplasms - genetics (8) 8
management (8) 8
medical research (8) 8
mesothelioma - pathology (8) 8
neoplasm metastasis (8) 8
oxaliplatin (8) 8
phase-iii (8) 8
quality-of-life (8) 8
randomized phase-iii (8) 8
systematic review (8) 8
antibodies, monoclonal - administration & dosage (7) 7
antineoplastic combined chemotherapy protocols - adverse effects (7) 7
biomarkers (7) 7
carcinoma (7) 7
carcinoma, non-small-cell lung - drug therapy (7) 7
carcinoma, non-small-cell lung - genetics (7) 7
colorectal neoplasms - genetics (7) 7
colorectal-cancer (7) 7
docetaxel (7) 7
genes (7) 7
kaplan-meier estimate (7) 7
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
by Waddell, Nicola and Pajic, Marina and Patch, Ann-Marie and Chang, David K and Kassahn, Karin S and Bailey, Peter and Johns, Amber L and Miller, David and Nones, Katia and Quek, Kelly and Quinn, Michael C. J and Robertson, Alan J and Fadlullah, Muhammad Z. H and Bruxner, Tim J. C and Christ, Angelika N and Harliwong, Ivon and Idrisoglu, Senel and Manning, Suzanne and Nourse, Craig and Nourbakhsh, Ehsan and Wani, Shivangi and Wilson, Peter J and Markham, Emma and Cloonan, Nicole and Anderson, Matthew J and Fink, J. Lynn and Holmes, Oliver and Kazakoff, Stephen H and Leonard, Conrad and Newell, Felicity and Poudel, Barsha and Song, Sarah and Taylor, Darrin and Waddell, Nick and Wood, Scott and Xu, Qinying and Wu, Jianmin and Pinese, Mark and Cowley, Mark J and Lee, Hong C and Jones, Marc D and Nagrial, Adnan M and Humphris, Jeremy and Chantrill, Lorraine A and Chin, Venessa and Steinmann, Angela M and Mawson, Amanda and Humphrey, Emily S and Colvin, Emily K and Chou, Angela and Scarlett, Christopher J and Pinho, Andreia V and Giry-Laterriere, Marc and Rooman, Ilse and Samra, Jaswinder S and Kench, James G and Pettitt, Jessica A and Merrett, Neil D and Toon, Christopher and Epari, Krishna and Nguyen, Nam Q and Barbour, Andrew and Zeps, Nikolajs and Jamieson, Nigel B and Graham, Janet S and Niclou, Simone P and Bjerkvig, Rolf and Grützmann, Robert and Aust, Daniela and Hruban, Ralph H and Maitra, Anirban and Iacobuzio-Donahue, Christine A and Wolfgang, Christopher L and Morgan, Richard A and Lawlor, Rita T and Corbo, Vincenzo and Bassi, Claudio and Falconi, Massimo and Zamboni, Giuseppe and Tortora, Giampaolo and Tempero, Margaret A and Gill, Anthony J and Eshleman, James R and Pilarsky, Christian and Scarpa, Aldo and Musgrove, Elizabeth A and Pearson, John V and Biankin, Andrew V and Grimmond, Sean M and Australian Pancreatic Canc Genome and Australian Pancreatic Cancer Genome Initiative
Nature, ISSN 0028-0836, 02/2015, Volume 518, Issue 7540, pp. 495 - 501
Journal Article
The Lancet Oncology, ISSN 1470-2045, 10/2017, Volume 18, Issue 10, pp. 1386 - 1396
Journal Article
FUTURE ONCOLOGY, ISSN 1479-6694, 04/2019, Volume 15, Issue 12, pp. 1363 - 1383
A substantial proportion of patients with nononcogene-addicted non-small-cell lung cancer (NSCLC) has 'aggressive disease', as reflected in short time to... 
anti-angiogenic therapy | INDUCTION CHEMOTHERAPY | OPEN-LABEL | SUPPORTIVE CARE | VINORELBINE PLUS CISPLATIN | ONCOLOGY | RANDOMIZED PHASE-III | PLATINUM-BASED CHEMOTHERAPY | 2ND-LINE TREATMENT | DOUBLE-BLIND | aggressive | STAGE-IV | non-small-cell lung cancer | PREVIOUSLY TREATED PATIENTS
Journal Article
PLOS ONE, ISSN 1932-6203, 01/2018, Volume 13, Issue 1, pp. e0191455 - e0191455
Background In advanced prostate cancer, osteoclast inhibitors prevent and palliate skeletal related events associated with bone metastases. However, it is... 
ZOLEDRONIC ACID | TROG 03.04 RADAR | CELLS | FREE SURVIVAL | MULTIDISCIPLINARY SCIENCES | OPEN-LABEL | PLACEBO-CONTROLLED TRIAL | PHASE-3 | RADIOTHERAPY | ORAL SODIUM CLODRONATE | PROGRESSION | Index Medicus
Journal Article
Mammalian genome : official journal of the International Mammalian Genome Society, ISSN 0938-8990, 12/2018, Volume 29, Issue 11-12, pp. 770 - 770
Some parts of the Abstract, Introduction and Discussion included uncited text from the following previously published chapter. 
Medicine, Experimental | Medical research | Research institutes | Immunotherapy | Proteomics
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 6, pp. 543 - 551
Summary Background Standard chemotherapy does not lead to long-term survival in patients with malignant pleural mesothelioma. Malignant pleural mesothelioma is... 
Hematology, Oncology and Palliative Medicine | CELL LUNG-CANCER | MULTIPLE-MYELOMA | THERAPY | ONCOLOGY | PLEURAL-MESOTHELIOMA | VEGF | DOUBLE-BLIND | SERUM | II TRIAL | TUMOR ANGIOGENESIS | NONINVASIVE DIAGNOSIS | Lung Neoplasms - drug therapy | Multivariate Analysis | Mesothelioma - pathology | Guanine - analogs & derivatives | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Palliative Care | Cisplatin - administration & dosage | Pleural Neoplasms - drug therapy | Angiogenesis Inhibitors - administration & dosage | Time Factors | Female | Angiogenesis Inhibitors - adverse effects | Pleural Neoplasms - pathology | Lung Neoplasms - blood supply | Thalidomide - adverse effects | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Linear Models | Treatment Outcome | Thalidomide - administration & dosage | Chi-Square Distribution | Mesothelioma - blood supply | Pemetrexed | Pleural Neoplasms - blood supply | Disease Progression | Mesothelioma - drug therapy | Biomarkers, Tumor - blood | Mesothelioma - blood | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Glutamates - administration & dosage | Pleural Neoplasms - blood | Aged | Lung Neoplasms - blood | Guanine - administration & dosage | Mesothelioma | Care and treatment | Chemotherapy | Thalidomide | Cancer
Journal Article
Journal Article
Mammalian Genome, ISSN 0938-8990, 12/2018, Volume 29, Issue 11-12, pp. 757 - 769
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2012, Volume 30, Issue 13, pp. 1505 - 1512
Purpose This preclinical and phase II study evaluated the efficacy and safety of the combination of cetuximab and erlotinib in metastatic colorectal cancer... 
TRIAL | CELLS | GEFITINIB | SOLID TUMORS | ONCOLOGY | MONOCLONAL-ANTIBODY-806 | OPEN-LABEL | INTERLEUKIN-6 | INHIBITOR AG1478 | EGFR | PLUS | Erlotinib Hydrochloride | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Drug Resistance, Neoplasm | Male | Molecular Targeted Therapy | Antibodies, Monoclonal, Humanized | Receptor, Epidermal Growth Factor - metabolism | Transfection | Time Factors | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Cetuximab | STAT3 Transcription Factor - genetics | STAT3 Transcription Factor - metabolism | Colorectal Neoplasms - mortality | Colorectal Neoplasms - enzymology | Kaplan-Meier Estimate | Proto-Oncogene Proteins - genetics | Treatment Outcome | Drug Synergism | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Analysis of Variance | Signal Transduction - drug effects | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cell Line, Tumor | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Cell Proliferation - drug effects | Mutation | Australia | Colorectal Neoplasms - pathology | Index Medicus
Journal Article